Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.
We have previously shown that a hexavalent group A streptococcal M protein-based vaccine evoked bactericidal antibodies after intramuscular injection. In the present study, we show that the hexavalent vaccine formulated with several different mucosal adjuvants and delivered intranasally induced serum and salivary antibodies that protected mice from intranasal challenge infections with virulent group A streptococci. The hexavalent vaccine was formulated with liposomes with or without monophosphorylated lipid A (MPL), cholera toxin B subunit with or without holotoxin, or proteosomes from Neisseria meningitidis outer membrane proteins complexed with lipopolysaccharide from Shigella flexneri. Intranasal immunization with the hexavalent vaccine mixed with these adjuvants resulted in significant levels of antibodies in serum 2 weeks after the final dose. Mean serum antibody titers were equivalent in all groups of mice except those that were immunized with hexavalent protein plus liposomes without MPL, which were significantly lower. Salivary antibodies were also detected in mice that received the vaccine formulated with the four strongest adjuvants. T-cell proliferative assays and cytokine assays using lymphocytes from cervical lymph nodes and spleens from mice immunized with the hexavalent vaccine formulated with proteosomes indicated the presence of hexavalent protein-specific T cells and a Th1-weighted mixed Th1-Th2 cytokine profile. Intranasal immunization with adjuvanted formulations of the hexavalent vaccine resulted in significant levels of protection (80 to 100%) following intranasal challenge infections with type 24 group A streptococci. Our results indicate that intranasal delivery of adjuvanted multivalent M protein vaccines induces protective antibody responses and may provide an alternative to parenteral vaccine formulations.
Hall
Mary A
MA
Department of Veterans Affairs Medical Center, University of Tennessee Health Science Center, Memphis, Tennessee 38104, USA.
Stroop
Steven D
SD
Hu
Mary C
MC
Walls
Michael A
MA
Reddish
Mark A
MA
Burt
David S
DS
Lowell
George H
GH
Dale
James B
JB
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000097:blood; D000918:Antibody Specificity; D000921:Antibody-Producing Cells / Q000276:immunology; D000942:Antigens, Bacterial; D001426:Bacterial Proteins / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D066298:In Vitro Techniques; D008081:Liposomes; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D012463:Saliva / Q000276:immunology; D013290:Streptococcal Infections / Q000276:immunology* / Q000517:prevention & control*; D022541:Streptococcal Vaccines / Q000008:administration & dosage*; D013297:Streptococcus pyogenes / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D016207:Cytokines; D008081:Liposomes; D022541:Streptococcal Vaccines